Recent advances in targeted therapy for glioblastoma

References

• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent GBM patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572-8
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5(2):144-51
   PubMedGoogle Scholar
• Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91
   PubMed Web of Science ®Google Scholar
• Weller M, Tabatabai G, Kästner B, et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: The DIRECTOR Trial. Clin Cancer Res 2015;21:2057-64
   PubMed Web of Science ®Google Scholar
• Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010;28:2051-7
   PubMed Web of Science ®Google Scholar
• Nagpal S. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant GBM. Neurosurg Clin N Am 2012;23(2):289-95
   PubMed Web of Science ®Google Scholar
• Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade GBMs. Exp Rev of AntiCan Ther 2013;13(12):1453-61
   PubMed Web of Science ®Google Scholar
• Levin VA, Wilson CB. Nitrosourea chemotherapy for primary malignant GBMs. Cancer Treat Rep 1976;60(6):719-24
   Google Scholar
• Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006;24(27):4412-17
   PubMed Web of Science ®Google Scholar
• Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27(8):1257-61
   PubMed Web of Science ®Google Scholar
• Belda-Iniesta C, de Castro Carpeño J, Sereno M, et al. Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. Clin Transl Oncol 2008;10(2):73-7
   PubMed Web of Science ®Google Scholar
• Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16(6):748-54
   PubMed Web of Science ®Google Scholar
• Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J of Rad Oncol Bio Phy 2011;80(2):347-53
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib–a phase II trial. Mol Cancer Ther 2011;10(6):1102-12
   PubMed Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Rev Cancer 2010;10(11):760-74
   PubMed Web of Science ®Google Scholar
• Peereboom DM, Ahluwalia MS, Ye X, et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncol 2013;15(4):490-6
   PubMed Web of Science ®Google Scholar
• Griffero F, Daga A, Marubbi D, et al. Different response of human GBM tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J Biol Chem 2009;284(11):7138-48
   PubMed Web of Science ®Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014;343(6166):72-6
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Dimitropoulos K, Argyriou AA, et al. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two GBM cell lines. Inves New Drug 2010;28(5):554-60
   Google Scholar
• Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother and Pharmacol 2010;65(2):353-61
   PubMed Web of Science ®Google Scholar
• Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother and Pharmacol 2012;69(6):1507-18
   PubMed Web of Science ®Google Scholar
• Reardon DA, Groves MD, Wen PY, et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant GBM. Clin Cancer Res 2013;19(4):900-8
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Kotoula V, Pentheroudakis G, et al. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade GBMs. J Neurol 2013;260(6):1469-80
   PubMed Web of Science ®Google Scholar
• A service of the U.S. National Institutes of Health. Clinicaltrials.gov. Available from: http://clinicaltrials.gov
   Google Scholar
• Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade GBM. Ann Oncol 2009;20(9):1596-603
   PubMed Web of Science ®Google Scholar
• Hartmann C, Muller N, Blaukat A, et al. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 2010;29(32):4517-27
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(31):4722-9
   PubMed Web of Science ®Google Scholar
• Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13(3):324-33
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1(1):41-8
   PubMed Web of Science ®Google Scholar
• Solomon MT, Selva JC, Figueredo J, et al. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade GBM patients: results from a randomized, double blind trial. BMC Cancer 2013;13:299
   PubMedGoogle Scholar
• Choi BD, Kuan CT, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral GBM. Proc Natl Acad Sci USA 2013;110(1):270-5
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Natl Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Batchelor TT, Zhang WT, et al. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69(13):5296-300
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26):3212-18
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Gerstner ER, Emblem KE, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci 2013;110(47):19059-64
   PubMed Web of Science ®Google Scholar
• Plate KH, Scholz A, Dumont DJ. Tumor angiogenesis and anti-angiogenic therapy in malignant GBMs revisited. Acta Neuropathol 2012;124(6):763-75
   PubMed Web of Science ®Google Scholar
• de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant GBM: a North American Brain Tumor Consortium study. J Clin Oncol 2011;29(19):2689-95
   PubMed Web of Science ®Google Scholar
• Kreisl TN, McNeill KA, Sul J, et al. A phase I/II trial of vandetanib for patients with recurrent malignant GBM. Neuro Oncol 2012;14(12):1519-26
   PubMed Web of Science ®Google Scholar
• Xu T, Chen J, Lu Y, et al. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant GBM: a systematic review and survival-gain analysis. BMC Cancer 2010;10:252
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009;14(11):1131-8
   PubMed Web of Science ®Google Scholar
• Roches Avastin approved in Japan for treatment of the most aggressive form of brain cancer. Available from: www.roche.com/media/store/releases/med-cor-2013-06-17.htm
   Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709-22
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):699-708
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009;15(16):5020-5
   PubMed Web of Science ®Google Scholar
• Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of anti-angiogenic therapy resistance. Clin Cancer Res 2013;19:1773-83
   PubMed Web of Science ®Google Scholar
• Westermark B, Heldin CH, Nistér M. Platelet-derived growth factor in human GBM. Glia 1995;15(3):257-63
   Google Scholar
• Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-316
   PubMed Web of Science ®Google Scholar
• Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant GBM. CA Cancer J Clin 2010;60(3):166-93
   PubMed Web of Science ®Google Scholar
• Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade GBM. Cancer 2012;118(19):4759-67
   Google Scholar
• Kinsella P, Clynes M, Amberger-Murphy V. Imatinib and docetaxel in combination can effectively inhibit GBM invasion in an in vitro 3D invasion assay. J Neurooncol 2011;101(2):189-98
   Google Scholar
• Erguven M, Yazihan N, Aktas E, et al. Carvedilol in GBM treatment alone and with imatinib in vitro. Int J Oncol 2010;36(4):857-66
   Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5(10):981-9
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol 2012;14(1):93-100
   PubMed Web of Science ®Google Scholar
• Drappatz J, Lee EQ, Hammond S, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade GBM. J Neurooncol 2012;107(1):133-8
   Google Scholar
• Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant GBM: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011;13(5):509-16
   PubMed Web of Science ®Google Scholar
• Friday BB, Anderson SK, Buckner JYu, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012;14(2):215-21
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology. (Williston Park) 2007;21(9 Suppl 3):13-20
   Google Scholar
• Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012;106(1):147-53
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(16):2712-18
   PubMed Web of Science ®Google Scholar
• Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012;118(22):5601-7
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1100-8
   PubMed Web of Science ®Google Scholar
• Eisele G, Wick A, Eisele AC, et al. Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neuroncol 2014;117(1):141-5
   Google Scholar
• Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol 2010;12(8):882-9
   PubMed Web of Science ®Google Scholar
• Grzmil M, Hemmings BA. Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim Biophys Acta 2013;1834(7):1371-80
   Google Scholar
• Vlachostergios PJ, Voutsadakis IA, Papandreou CN. Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma. Cell Bio Toxicol 2013;29(4):199-211
   Google Scholar
• Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant GBM. J Neurooncol 2010;100(1):95-103
   PubMed Web of Science ®Google Scholar
• Ahluwalia MS, Patton C, Stevens G, et al. Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. J Neurooncol 2011;102(2):317-21
   Google Scholar
• Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells–from concept to clinical application. Cancer Lett 2013;338(1):32-40
   Google Scholar
• Hovinga KE, Shimizu F, Wang R, et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010;28(6):1019-29
   PubMed Web of Science ®Google Scholar
• Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468(7325):829-33
   PubMed Web of Science ®Google Scholar
• Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30(19):2307-13
   PubMed Web of Science ®Google Scholar
• Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol 2010;80(5):654-65
   PubMed Web of Science ®Google Scholar
• Ulasov IV, Nandi S, Dey M, et al. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) GBM stem cells to temozolomide therapy. Mol Med 2011;17(1-2):103-12
   PubMed Web of Science ®Google Scholar
• Gallia GL, Tyler BM, Hann CL, et al. Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells. Mol Cancer Ther 2009;8(2):386-93
   PubMed Web of Science ®Google Scholar
• Kaur B, Khwaja FW, Severson EA, et al. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7(2):134-53
   PubMed Web of Science ®Google Scholar
• Tang CM, Yu J. Hypoxia-inducible factor-1 as a therapeutic target in cancer. J Gastroenterol Hepatol 2013;28(3):401-5
   PubMed Web of Science ®Google Scholar
• Vasic V, Gailly P, Kondo S, et al. Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008;62(1):211-21
   Google Scholar
• Li Y, Guessous F, Zhang Y, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69(19):7569-76
   PubMed Web of Science ®Google Scholar
• Luan S, Sun L, Huang F. MicroRNA-34a: a novel tumor suppressor in p53-mutant GBM cell line U251. Arch Med Res 2010;41(2):67-74
   PubMed Web of Science ®Google Scholar
• Chan XH, Nama S, Gopal F, et al. Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep 2012;2(3):591-602
   PubMed Web of Science ®Google Scholar
• Slaby O, Lakomy R, Fadrus P, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010;57(3):264-9
   PubMed Web of Science ®Google Scholar
• Galldiks N, Berhorn T, Blau T, et al. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. J Neurooncol 2013;112(2):209-15
   Google Scholar
• Balducci M, Fiorentino A, De Bonis P, et al. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials. Strahlenther Onkol 2013;189(11):926-31
   Google Scholar
• Zustovich F, Landi L, Lombardi G, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. AntiCan Res 2013;33(8):3487-94
   PubMed Web of Science ®Google Scholar
• Reddy K, Damek D, Gaspar LE, et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J of Rad Oncol Bio Phy 2012;84(3):655-60
   Google Scholar
• Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J of Rad Oncol Bio Phy 2012;83(1):93-9
   PubMed Web of Science ®Google Scholar
• Lou E, Peters KB, Sumrall AL, et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med 2013;2(2):185-95
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003;5(2):79-88
   PubMed Web of Science ®Google Scholar
• Quinn JA, Jiang SX, Carter J, et al. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009;15(3):1064-8
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006;24(27):4412-17
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomized controlled phase 2 trial. Lancet Oncol 2014;15(9):943-53
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013;31(26):3212-18
   PubMed Web of Science ®Google Scholar